News | December 12, 2023
Devyser has been awarded a tender for Devyser’s CFTR fragment analysis products, that are used for screening and confirmation of cystic fibrosis. The tender with the University Hospital in Bologna is valid for a period of three years. Indicative order value is estimated to amount to approximately 2 million SEK annually.
"The tender strengthens our already strong position in the Italian market, and I am very proud of the entire team who made this happen", says CEO Fredrik Alpsten. "National and regional screening programs represent important opportunities for us and securing this tender is another confirmation of the competitiveness of our high quality and simple CFTR genetic analysis solutions."
Devyser’s CFTR fragment analysis products are highly sensitive CE-IVD labelled genotyping tests for detection of sequence variants in cystic fibrosis transmembrane conductance regulator (CFTR) gene. Devyser’s CFTR tests are used in the confirmation of cystic fibrosis and for screening of genetic variants in newborns and adults.
For more information, please contact:
Fredrik Alpsten, CEO
E-mail: fredrik.alpsten@devyser.com
Telephone: +46 70 667 31 06
Theis Kipling, CCO
E-mail: theis.kipling@devyser.com
Telephone: +46 73 598 07 76
About Devyser
Devyser develops, manufactures and sells diagnostic solutions and analysis services to clinical laboratories in more than 50 countries. Our products are used for advanced genetic testing in the hereditary disease, oncology and transplant fields, to enable targeted cancer treatment, the diagnosis of a large number of genetic diseases, and transplant patient follow-up. Devyser's products, and unique, patented solution requiring only one test tube, simplify genetic testing processes, improve sample throughput, minimize hands-on time and deliver rapid results. Our goal is for every patient to receive a correct diagnosis in the shortest possible time. Sustainability is a central part of our business and an important prerequisite for long term value creation.
Devyser was founded in 2004 and is based in Stockholm, Sweden with eight in-house sales offices in Europe and the US. The company also runs Devyser Genomic Laboratories, a CLIA certified laboratory in Atlanta, US. In 2022, Devyser's quality management system was certified according to the IVDR and a number of the company's products have since been certified according to the IVDR.
Devyser's shares are listed on the Nasdaq First North Premier Growth Market Stockholm (ticker: DVYSR). The company's Certified Adviser is Redeye AB.
